Ophthalmology Focus Valeo Pharma prioritizes ophthalmology and has a distribution partnership with Novartis for an eye treatment, signaling a mature Canadian ophthalmology channel. This creates opportunities to introduce complementary ophthalmic therapies, devices, or co-promoted products that can leverage their market access and hospital network.

Respiratory Growth With a focus on Respiratory/Allergy, Valeo seeks innovative prescription products in Canada. Opportunities exist to collaborate on new inhaled therapies, nasal formulations, or related devices that fit their portfolio and distribution capabilities.

Hospital Specialty Channel Valeo actively targets hospital specialty products and maintains infrastructure to manage all stages of commercialization. This presents sales opportunities in hospital-based therapies, sterile injectables, or intravenous medications, and could align with contracts with health systems or group purchasing organizations.

Strategic Partnerships Strategic growth activity and leadership changes point to an openness to partnerships and accelerated expansion. Potential opportunities include licensing deals, co-development arrangements, or strategic investments that help scale Valeo's portfolio and speed market entry.

Commercialization Readiness Valeo reports a growing revenue footprint and has a robust commercialization platform with a modern tech stack. This readiness suggests you can offer regulatory affairs outsourcing, market access and payer strategies, or digital marketing and analytics services to accelerate launches in Canada.